TriangleNCT02860286 · OUTCOME
Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): t1/2
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- Hour
- Interval / dispersion
- Standard Deviation
- Time frame
- Cycle 1 Day 15: pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 12 post-dose
What was measured
Results from assessing the half-life of Tazemetostat and its metabolite shown below
Groups in this outcome
Part 1(Pharmacokinetics)
Oral Tazemetostat 800mg BID Tazemetostat: Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
| Group | Source count |
|---|---|
| Part 1(Pharmacokinetics) | 13 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1(Pharmacokinetics) | 3.06 | 0.307 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 0.307
- value
- 3.06
- denoms
- counts
- group Id
- OG000
- value
- 13
- units
- Participants
- description
- Results from assessing the half-life of Tazemetostat and its metabolite shown below
- dispersion Type
- Standard Deviation
- groups
- description
- Oral Tazemetostat 800mg BID Tazemetostat: Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
- id
- OG000
- title
- Part 1(Pharmacokinetics)
- param Type
- MEAN
- reporting Status
- POSTED
- time Frame
- Cycle 1 Day 15: pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 12 post-dose
- title
- Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): t1/2
- type
- PRIMARY
- unit Of Measure
- Hour
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice